Adicet Bio (ACET) Change in Accured Expenses (2017 - 2026)

Adicet Bio's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 47.88% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $3.0 million (up 220.95% YoY), while the FY2025 annual figure was $1.9 million, up 194.16% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.1 million, down from $1.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.0 million in Q4 2022, with the low at -$2.2 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $17000.0 (2023), against an average of $312823.5.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses surged 2066.67% in 2022, then tumbled 2064.71% in 2024.
• Adicet Bio's Change in Accured Expenses stood at $5.0 million in 2022, then slumped by 85.68% to $714000.0 in 2023, then slumped by 224.51% to -$889000.0 in 2024, then surged by 317.55% to $1.9 million in 2025, then plunged by 159.2% to -$1.1 million in 2026.
• Business Quant data shows ACET's Change in Accured Expenses at -$1.1 million in Q1 2026, $1.9 million in Q4 2025, and $538000.0 in Q3 2025.